statistiche ricercatore

Continente	#
NA - Nord America	1.193
AS - Asia	624
EU - Europa	362
SA - Sud America	78
Continente sconosciuto - Info sul continente non disponibili	33
OC - Oceania	9
AF - Africa	8
Totale	2.307

Nazione	#
US - Stati Uniti d'America	1.161
SG - Singapore	239
CN - Cina	126
IT - Italia	103
VN - Vietnam	84
BR - Brasile	63
DE - Germania	44
GB - Regno Unito	40
AT - Austria	39
HK - Hong Kong	38
BD - Bangladesh	30
ID - Indonesia	23
FR - Francia	22
PL - Polonia	22
CA - Canada	20
JP - Giappone	19
FI - Finlandia	16
IN - India	16
TR - Turchia	15
SE - Svezia	13
RU - Federazione Russa	12
ES - Italia	10
UA - Ucraina	9
AU - Australia	8
AR - Argentina	7
NO - Norvegia	7
PK - Pakistan	7
BE - Belgio	5
CH - Svizzera	5
IQ - Iraq	5
LT - Lituania	5
MX - Messico	5
ZA - Sudafrica	5
NL - Olanda	4
MY - Malesia	3
PA - Panama	3
EC - Ecuador	2
IE - Irlanda	2
JO - Giordania	2
KG - Kirghizistan	2
NP - Nepal	2
PH - Filippine	2
PS - Palestinian Territory	2
TW - Taiwan	2
VE - Venezuela	2
AL - Albania	1
BO - Bolivia	1
CO - Colombia	1
EE - Estonia	1
EG - Egitto	1
GR - Grecia	1
HN - Honduras	1
IL - Israele	1
JM - Giamaica	1
KE - Kenya	1
KZ - Kazakistan	1
NZ - Nuova Zelanda	1
PR - Porto Rico	1
PY - Paraguay	1
QA - Qatar	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	2.274

Nome	#
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists	308
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia	277
Therapeutic potential of RGS4 blockade in movement disorders	239
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes	216
NOP receptor ligands and Parkinson’s disease	205
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models	164
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata	164
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats	155
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives	151
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease	149
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia	143
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia	136
Totale	2.307

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	95	2	2	4	2	2	14	8	14	6	7	11	23
2022/2023	171	14	26	11	22	27	24	6	5	19	0	11	6
2023/2024	93	8	4	4	6	8	13	4	11	2	5	4	24
2024/2025	367	5	9	37	5	27	67	2	16	46	65	48	40
2025/2026	1.213	134	34	69	136	202	78	148	80	103	130	76	23
2026/2027	30	30	0	0	0	0	0	0	0	0	0	0	0
Totale													2.307

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara